Faaborg Pharma - IP ApS — Credit Rating and Financial Key Figures
CVR number: 43517252
Markedspladsen 13 A, 5600 Faaborg
Income statement (kDKK)
2023 | 2024 | |
---|---|---|
Fiscal period length | 12 | 12 |
Net sales | ||
Gross profit | - 263.58 | - 247.66 |
Total depreciation | - 550.41 | - 662.78 |
EBIT | - 813.99 | - 910.45 |
Other financial income | 9.05 | 10.27 |
Other financial expenses | - 129.90 | - 246.16 |
Pre-tax profit | - 934.84 | -1 146.34 |
Income taxes | 177.33 | 250.99 |
Net earnings | - 757.51 | - 895.36 |
Assets (kDKK)
2023 | 2024 | |
---|---|---|
Development expenditure | 211.02 | |
Intangible rights | 2 283.79 | 1 958.13 |
Intangible assets total | 2 283.79 | 2 169.15 |
Tangible assets total | ||
Investments total | ||
Long term receivables total | ||
Inventories total | ||
Current trade debtors | 0.33 | 0.40 |
Current amounts owed by group member comp. | 402.78 | 409.05 |
Current other receivables | 64.97 | 14.87 |
Current deferred tax assets | 177.33 | 283.00 |
Short term receivables total | 645.41 | 707.31 |
Cash and bank deposits | 0.11 | 22.94 |
Cash and cash equivalents | 0.11 | 22.94 |
Balance sheet total (assets) | 2 929.31 | 2 899.40 |
Equity and liabilities (kDKK)
2023 | 2024 | |
---|---|---|
Share capital | 40.00 | 40.00 |
Retained earnings | - 757.51 | |
Profit of the financial year | - 757.51 | - 895.36 |
Shareholders equity total | - 717.51 | -1 612.86 |
Non-current liabilities total | ||
Current loans from credit institutions | 3 051.65 | 3 564.50 |
Current trade creditors | 21.17 | 276.18 |
Current owed to group member | 573.99 | 671.59 |
Current liabilities total | 3 646.81 | 4 512.26 |
Balance sheet total (liabilities) | 2 929.31 | 2 899.40 |
CreditReports API
- Company information
- Financial data
- Credit risk data
- All 400,000+ Danish companies
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions

... and more!
No registration needed.